The Off-Label Use of POM Wonderful: Using Section 43(a) to Eliminate Misleading Off-Label Drug Promotion
On his way home from the hospital with his newborn son, a hit-and-run accident left Jeremy Lew with a severely injured spine. Lew underwent surgery, during which his doctor implanted a device approved by the Food and Drug Administration (FDA) between his cervical vertebrae. The treatment initially a...
Gespeichert in:
Veröffentlicht in: | Washington and Lee law review 2018-01, Vol.75 (1), p.593-646 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 646 |
---|---|
container_issue | 1 |
container_start_page | 593 |
container_title | Washington and Lee law review |
container_volume | 75 |
creator | Hurley, Christopher A |
description | On his way home from the hospital with his newborn son, a hit-and-run accident left Jeremy Lew with a severely injured spine. Lew underwent surgery, during which his doctor implanted a device approved by the Food and Drug Administration (FDA) between his cervical vertebrae. The treatment initially appeared successful, but Lew later began suffering from "unrelenting" pain, barely able to pick up his children. Although the FDA approved the device, the agency intended it for use only in the mid-to-lower spinal column. The off-label use of the medical device caused Lew unimaginable pain as a result of his nerve injury, and could have further caused sterility, infection, or urinary problems. Advocates of off-label medication use tout highly successful treatments that have saved lives even when approved treatments have failed. Typically, the FDA weighs a medication's benefits against potentially harmful side effects as part of its New Drug Application process, established by the Food, Drug, and Cosmetic Act. |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2050582598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2050582598</sourcerecordid><originalsourceid>FETCH-proquest_journals_20505825983</originalsourceid><addsrcrecordid>eNqNjMsKwjAURIMoWB__cMGNLgqxaWp16wMXioKKS4l600Ziokn7_7YguHU1cObMNEgwnsZRmCQ8bZKA0piFNE5Ym3S8f1BKecQmAcmPOcJOynAjrqjh5BGshP1uC2dr7uhkqWcVVSaDA94KZQ3EbChGUFhYavVURhQIW-U1intt_b4Wrsxg7-zT1rMeaUmhPfa_2SWD1fI4X4cvZ98l-uLysKUzVXWJKKc8jfg0Zf9ZH7heRlc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2050582598</pqid></control><display><type>article</type><title>The Off-Label Use of POM Wonderful: Using Section 43(a) to Eliminate Misleading Off-Label Drug Promotion</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>HeinOnline Law Journal Library</source><creator>Hurley, Christopher A</creator><creatorcontrib>Hurley, Christopher A</creatorcontrib><description>On his way home from the hospital with his newborn son, a hit-and-run accident left Jeremy Lew with a severely injured spine. Lew underwent surgery, during which his doctor implanted a device approved by the Food and Drug Administration (FDA) between his cervical vertebrae. The treatment initially appeared successful, but Lew later began suffering from "unrelenting" pain, barely able to pick up his children. Although the FDA approved the device, the agency intended it for use only in the mid-to-lower spinal column. The off-label use of the medical device caused Lew unimaginable pain as a result of his nerve injury, and could have further caused sterility, infection, or urinary problems. Advocates of off-label medication use tout highly successful treatments that have saved lives even when approved treatments have failed. Typically, the FDA weighs a medication's benefits against potentially harmful side effects as part of its New Drug Application process, established by the Food, Drug, and Cosmetic Act.</description><identifier>ISSN: 0043-0463</identifier><identifier>EISSN: 1942-6658</identifier><language>eng</language><publisher>Lexington: Washington & Lee University, School of Law</publisher><subject>Advertising ; Drugs ; Enforcement ; FDA approval ; Federal regulation ; First Amendment-US ; Hit & run accidents ; Jurisdiction ; Lanham Act 1946-US ; Litigation ; Marketing ; Medical equipment ; Medical treatment ; Pharmaceutical industry ; Side effects</subject><ispartof>Washington and Lee law review, 2018-01, Vol.75 (1), p.593-646</ispartof><rights>Copyright Washington & Lee University, School of Law Winter 2018</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Hurley, Christopher A</creatorcontrib><title>The Off-Label Use of POM Wonderful: Using Section 43(a) to Eliminate Misleading Off-Label Drug Promotion</title><title>Washington and Lee law review</title><description>On his way home from the hospital with his newborn son, a hit-and-run accident left Jeremy Lew with a severely injured spine. Lew underwent surgery, during which his doctor implanted a device approved by the Food and Drug Administration (FDA) between his cervical vertebrae. The treatment initially appeared successful, but Lew later began suffering from "unrelenting" pain, barely able to pick up his children. Although the FDA approved the device, the agency intended it for use only in the mid-to-lower spinal column. The off-label use of the medical device caused Lew unimaginable pain as a result of his nerve injury, and could have further caused sterility, infection, or urinary problems. Advocates of off-label medication use tout highly successful treatments that have saved lives even when approved treatments have failed. Typically, the FDA weighs a medication's benefits against potentially harmful side effects as part of its New Drug Application process, established by the Food, Drug, and Cosmetic Act.</description><subject>Advertising</subject><subject>Drugs</subject><subject>Enforcement</subject><subject>FDA approval</subject><subject>Federal regulation</subject><subject>First Amendment-US</subject><subject>Hit & run accidents</subject><subject>Jurisdiction</subject><subject>Lanham Act 1946-US</subject><subject>Litigation</subject><subject>Marketing</subject><subject>Medical equipment</subject><subject>Medical treatment</subject><subject>Pharmaceutical industry</subject><subject>Side effects</subject><issn>0043-0463</issn><issn>1942-6658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNjMsKwjAURIMoWB__cMGNLgqxaWp16wMXioKKS4l600Ziokn7_7YguHU1cObMNEgwnsZRmCQ8bZKA0piFNE5Ym3S8f1BKecQmAcmPOcJOynAjrqjh5BGshP1uC2dr7uhkqWcVVSaDA94KZQ3EbChGUFhYavVURhQIW-U1intt_b4Wrsxg7-zT1rMeaUmhPfa_2SWD1fI4X4cvZ98l-uLysKUzVXWJKKc8jfg0Zf9ZH7heRlc</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Hurley, Christopher A</creator><general>Washington & Lee University, School of Law</general><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X1</scope><scope>7XB</scope><scope>87Z</scope><scope>8A9</scope><scope>8AO</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ANIOZ</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRAZJ</scope><scope>FRNLG</scope><scope>F~G</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>L.-</scope><scope>M0C</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20180101</creationdate><title>The Off-Label Use of POM Wonderful: Using Section 43(a) to Eliminate Misleading Off-Label Drug Promotion</title><author>Hurley, Christopher A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_20505825983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Advertising</topic><topic>Drugs</topic><topic>Enforcement</topic><topic>FDA approval</topic><topic>Federal regulation</topic><topic>First Amendment-US</topic><topic>Hit & run accidents</topic><topic>Jurisdiction</topic><topic>Lanham Act 1946-US</topic><topic>Litigation</topic><topic>Marketing</topic><topic>Medical equipment</topic><topic>Medical treatment</topic><topic>Pharmaceutical industry</topic><topic>Side effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Hurley, Christopher A</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Accounting & Tax Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Accounting & Tax Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Accounting, Tax & Banking Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Accounting, Tax & Banking Collection (Alumni)</collection><collection>Business Premium Collection (Alumni)</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Washington and Lee law review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hurley, Christopher A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Off-Label Use of POM Wonderful: Using Section 43(a) to Eliminate Misleading Off-Label Drug Promotion</atitle><jtitle>Washington and Lee law review</jtitle><date>2018-01-01</date><risdate>2018</risdate><volume>75</volume><issue>1</issue><spage>593</spage><epage>646</epage><pages>593-646</pages><issn>0043-0463</issn><eissn>1942-6658</eissn><abstract>On his way home from the hospital with his newborn son, a hit-and-run accident left Jeremy Lew with a severely injured spine. Lew underwent surgery, during which his doctor implanted a device approved by the Food and Drug Administration (FDA) between his cervical vertebrae. The treatment initially appeared successful, but Lew later began suffering from "unrelenting" pain, barely able to pick up his children. Although the FDA approved the device, the agency intended it for use only in the mid-to-lower spinal column. The off-label use of the medical device caused Lew unimaginable pain as a result of his nerve injury, and could have further caused sterility, infection, or urinary problems. Advocates of off-label medication use tout highly successful treatments that have saved lives even when approved treatments have failed. Typically, the FDA weighs a medication's benefits against potentially harmful side effects as part of its New Drug Application process, established by the Food, Drug, and Cosmetic Act.</abstract><cop>Lexington</cop><pub>Washington & Lee University, School of Law</pub></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0043-0463 |
ispartof | Washington and Lee law review, 2018-01, Vol.75 (1), p.593-646 |
issn | 0043-0463 1942-6658 |
language | eng |
recordid | cdi_proquest_journals_2050582598 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; HeinOnline Law Journal Library |
subjects | Advertising Drugs Enforcement FDA approval Federal regulation First Amendment-US Hit & run accidents Jurisdiction Lanham Act 1946-US Litigation Marketing Medical equipment Medical treatment Pharmaceutical industry Side effects |
title | The Off-Label Use of POM Wonderful: Using Section 43(a) to Eliminate Misleading Off-Label Drug Promotion |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A01%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Off-Label%20Use%20of%20POM%20Wonderful:%20Using%20Section%2043(a)%20to%20Eliminate%20Misleading%20Off-Label%20Drug%20Promotion&rft.jtitle=Washington%20and%20Lee%20law%20review&rft.au=Hurley,%20Christopher%20A&rft.date=2018-01-01&rft.volume=75&rft.issue=1&rft.spage=593&rft.epage=646&rft.pages=593-646&rft.issn=0043-0463&rft.eissn=1942-6658&rft_id=info:doi/&rft_dat=%3Cproquest%3E2050582598%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2050582598&rft_id=info:pmid/&rfr_iscdi=true |